Surgical Innovations Group plc
("Surgical Innovations", or the "Group")
Notice of Annual Results
Analyst and Investor briefing
Surgical Innovations Group plc (AIM: SUN), the designer, manufacturer and distributor of innovative technology for minimally invasive surgery, announces that it will release its audited results for the year ended 31 December 2021 on Wednesday 23 March 2022.
Analyst briefing
A briefing open to analysts will take place remotely via video conference call on Wednesday 23 March 2022 at 9.30am. If you would like the details of this call please contact Walbrook PR on si@walbrookpr.com
Investor briefing
David Marsh, Chief Executive Officer, and Charmaine Day, Chief Financial Officer, will provide a live presentation relating to the final results via the Investor Meet Company platform on 23 March 2022 at 4:30pm GMT.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.
Investors can sign up to Investor Meet Company for free and add to meet Surgical Innovations Group plc via:
https://www.investormeetcompany.com/surgical-innovations-group-plc/register-investor
Investors who already follow Surgical Innovations Group plc on the Investor Meet Company platform will automatically be invited.
For further information please contact:
Surgical Innovations Group plc | www sigroupplc com | ||
David Marsh, CEO | Tel: 0113 230 7597 | ||
Charmaine Day, CFO | | ||
| | | ||
Singer Capital Markets (Nominated Adviser & Broker) | Tel: 020 7496 3000 | ||
Aubrey Powell / Rachel Hayes | | ||
| | | ||
Walbrook PR (Financial PR & Investor Relations) | Tel: 020 7933 8780 or si@walbrookpr.com | ||
Paul McManus / Lianne Applegarth | Mob: 07980 541 893 / 07584 391 303 | ||
About Surgical Innovations Group plc
The Group specialises in the design, manufacture, sale and distribution of innovative, high quality medical products, primarily for use in minimally invasive surgery. Our product and business development is guided and supported by a key group of nationally and internationally renowned surgeons across the spectrum of minimally invasive surgical activity.
We design and manufacture and source our branded port access systems, surgical instruments and retraction devices which are sold directly in the UK home market through our subsidiary, Elemental Healthcare, and exported widely through a global network of trusted distribution partners. Many of our products in this field are based on a "resposable" concept, in which the products are part reusable, part disposable, offering a high quality and environmentally responsible solution at a cost that is competitive against fully disposable alternatives.
Elemental also has exclusive UK distribution for a select group of specialist products employed in laparoscopy, bariatric and metabolic surgery, hernia repair and breast reconstruction.
In addition, we design and develop medical devices for carefully selected OEM partners and have also collaborated with a major UK industrial partner to provide precision engineering solutions to complex problems outside the medical arena.
We aim for our brands to be recognised and respected by healthcare professionals in all major geographical markets in which we operate and provide by development, partnership or acquisition a broad portfolio of cost effective, procedure specific surgical instruments and implantable devices that offer reliable solutions to genuine clinical needs in the operating theatre environment.
Further information
Further details of the Group's businesses and products are available on the following websites:
To receive regular updates by email, please contact si@walbrookpr.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.